Risk Factors for Autism Spectrum Disorder in Pediatric Tuberous Sclerosis Complex

Overview

This retrospective study analyzed clinical data from children with tuberous sclerosis complex (TSC) to identify risk factors associated with autism spectrum disorder (ASD). Findings highlight the role of mTOR pathway alterations and clinical features such as seizure history and genetic mutations in ASD development among TSC patients.

Background

Tuberous sclerosis complex (TSC) is a genetic disorder characterized by seizures, skin manifestations, and hamartomas, with an autosomal dominant inheritance pattern. Autism spectrum disorder (ASD) frequently co-occurs in TSC patients, affecting approximately 21% of children with TSC. Both conditions share dysregulation of the mTOR signaling pathway, making TSC an ideal model for studying ASD pathogenesis. Early identification of ASD in TSC patients may improve management and therapeutic interventions.

Data Highlights

Key Findings

• Approximately 21% of children with TSC were diagnosed with ASD using DSM-5 criteria and ADOS assessment.
• Children with TSC and ASD had a higher frequency of seizures and required more anti-seizure medications compared to those without ASD.
• TSC2 gene mutations were significantly associated with increased risk of ASD in TSC patients.
• Alterations in the mTOR signaling pathway were prevalent in TSC children with ASD, supporting its role in ASD pathogenesis.
• Early ASD screening starting at 12 months using ADOS-M 0 version facilitated identification of social communication deficits in TSC patients.

Clinical Implications

Clinicians should maintain a high index of suspicion for ASD in children with TSC, especially those with TSC2 mutations and frequent seizures. Early screening using standardized tools like ADOS can enable timely diagnosis and intervention. Understanding the role of mTOR pathway dysregulation may guide targeted therapies to improve neurodevelopmental outcomes in this population.

Conclusion

This study underscores the significant association between mTOR pathway alterations, seizure burden, and genetic factors with ASD in pediatric TSC patients. Early identification and targeted management strategies are essential to address the complex neurodevelopmental challenges in this group.

References

1. TSC Genetic Testing and Clinical Features, 2012 International Consensus
2. American Psychiatric Association, 2013 -- DSM-5 Definition of ASD
3. Prevalence of ASD in TSC Children, Prior Studies
4. mTOR Pathway Role in TSC and ASD, Molecular Studies
5. Animal Models of TSC2 Knockout and ASD Phenotype
6. ADOS Assessment and ASD Diagnosis in TSC Patients